<DOC>
	<DOCNO>NCT02561234</DOCNO>
	<brief_summary>This first-in-human study safety increase dose level AEB1102 patient advance cancer . The study also evaluate amount AEB1102 blood , effect AEB1102 blood amino acid level tumor growth .</brief_summary>
	<brief_title>A Multiple Dose , Dose Escalation Trial AEB1102 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>In phase I multiple dose , dose escalation study utilize classic 3+3 design . Sequential cohort patient receive AEB1102 IV weekly one series increase dose level . Dose escalation dependent frequency specific dose-limiting toxicity prior cohort patient . The study determine maximum tolerate dose ( MTD ) AEB1102 , evaluate safety profile compound , assess pharmacokinetic profile AEB1102 , determine effect AEB1102 blood arginine level evaluate anti-tumor activity AEB1102 . Following determination MTD , additional cohort ~20 patient specific solid tumor subtype enrol treated AEB1102 MTD .</detailed_description>
	<criteria>advanced solid tumor fail standard therapyis candidate Phase 1 treatment adequate organ function : Hgb ≥10 , ANC ≥ 1.5 , plt ≥ 100,000 ; AST/ALT &lt; 2.5x ULN , bilirubin &lt; 2.0 ; serum creatinine ≤ 1.5x ULN ECOG score 02 willing use physician approve birth control method primary CNS malignancy history untreated brain mets leptomeningeal disease spinal cord compression effect prior anticancer therapy recover grade &lt; 2 know HIV active infection major surgery within 2 week history another malignancy within 2 year prior</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>